A cross-sectional hospital based study of clinical and. patients from central rural India
|
|
- Geoffrey Bell
- 5 years ago
- Views:
Transcription
1 original article A cross-sectional hospital based study of clinical and patients from central rural India Sachin Ratanlal Agrawal, Iadarilang Tiewsoh, Atulsingh Rajput, Ajitprasad Jain Access this article online Website: DOI: / Quick Response Code: ABSTRACT Introduction: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder, the expression of which is greatly influenced by the combined effect of genetic, environmental, demographic and geographical factors. Various studies regarding clinical and immunological profile of SLE patients in India has been reported from a different region of India, especially from the urban area. We performed this study to understand the clinical and immunological profile of the SLE patients presenting to tertiary care center in rural central India. Materials and Methods: This study was conducted at a rural teaching hospital in central India. All patients records from 2007 to 2012 available with hospital having a discharge diagnosis of SLE and fulfilling the revised American College of Rheumatology criteria (1997) for SLE were analyzed regarding clinical and immunological profile. Results: We found 87 SLE patients out of 52,133 patients admitted in medicine department from 2007 to 2012 in the hospital record and included in the analysis. Nearly, 98% patients were female and 84% patients were under the age of 40 years. Common features present in these patients were immunological (97.7%), mucocutaneous (83.9%), hematological (72.4%) and renal (69.0%). Malar rash was the most common clinical feature presented in 71.3% patients followed by photosensitivity (63.2%) and oral ulcers (42.5%). Lymphopenia was the most common hematological abnormality present in 48.3%. Involvement of neurological, cardiovascular and respiratory system was found to be less common. Anti-nuclear antibodies were found to be positive in nearly 98% patients. Conclusion: Analysis of clinical profile of hospitalized SLE patients shows that the disease is more common in female patients, especially during the child bearing age group. The present study shows high frequency of mucocutaneous, hematological and renal manifestation in these patients. Key words: Central rural India, clinical and immunological profile, systemic lupus erythematosus Department of Internal Medicine, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra, India Address for correspondence: Dr. Sachin Ratanlal Agrawal, Department of Internal Medicine, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha , Maharashtra, India. dragrawal82@gmail.com 33
2 INTRODUCTION Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder affecting mainly female gender especially during child bearing age group. The prevalence rate has been reported to be 52/100,000 populations in United States with higher rates reported among black and Hispanic group. [1] Review study conducted from Asia has shown the prevalence rate of disease from 30 to 50/100,000 population. [2] One prevalence study conducted from rural India has shown very low prevalence rate (3.2/100,000 population). [3] In another study conducted in Eastern India found that 3.9% of the children in the rheumatology department had SLE. [4] However, larger epidemiological studies are needed to confirm the finding of these studies regarding the prevalence of disease in India. Due to the role of estrogen in etiopathogenesis of disease, SLE is more common in female as compare with male, especially in child bearing age group with a ratio ranging from 7:1 to 15:1. [5] The disease expression is greatly influenced by the combined effect of genetic, environmental, demographic and geographical factors. Genetic factor superimposed on certain environmental factors plays a very pivotal role in manifesting abnormal immunological response. Considerable variation has been observed regarding various clinical manifestation of SLE among various ethnic groups as well as various geographical regions. The first case of SLE in India was reported in [6] Subsequently, studies have been conducted in different parts of the country describing the encountered manifestations in the Indian population with SLE. Various studies regarding clinical and immunological profile of SLE patients in India has been reported from different region of India. [7-12] Most of these studies come from northern or western part of India and only one study has been reported from central India. [13] Thus, there exists a gap in our understanding regarding clinical and immunological profile of SLE patients, especially from rural India. We performed this study to understand the clinical and immunological profile of the SLE patients presenting to tertiary care center in rural central India. MATERIALS AND METHODS Setting The study was conducted in Kasturba Hospital Sevagram, which is a 648-bedded tertiary teaching hospital. All patients who are discharge from the hospital are given electronic discharge summary, which consist of detail clinical history, examination and relevant investigations. All discharge diagnosis and summaries are filed with hospital information system and classified as per international classification of disease-10. Data collection We screened retrospectively all patients admitted to medicine department from the period of through the hospital information system. We chose this period because detail information about the patient was not available through hospital information system prior to this period. All patients having a discharge diagnosis of SLE and fulfilling the revised American College of Rheumatology (ACR) criteria (1997) for SLE were included in the study. We collected the detail information of all these patients with respect to demographic characteristics, duration of disease and assessment of various organs involvement like cutaneous, musculoskeletal, renal, gastrointestinal tract, nervous and cardiopulmonary. We collected data regarding various investigation including complete blood count, urine microscopic examination, 24 h urine protein excretion, serum creatinine, blood urea, chest radiograph and electrocardiogram. We retrieved the information regarding auto antibodies level in all included patients mainly antinuclear antibodies (ANAs) and anti-double-stranded deoxyribonucleic acid (Ds DNA) antibodies. However, due to financial constraints, anti-ds DNA antibodies level could be obtained only in 49 patients out of 87. The Institutional Ethics Committee approved the study design. We did not collect any personal identity information from the discharge certificates. Analysis We did a descriptive analysis of all demographic features of all included patients. We performed the analysis of all clinical features present in SLE patients and calculated the cumulative percentage frequency of all clinical features present in SLE patients. We also calculated the cumulative percentage frequency of various systems involved in SLE patients. RESULTS Out of 52,133 patients admitted in medicine department from 2007 to 2012, 87 patients were found to have SLE. 85 (97.7%) patients were female and 2 (2.3%) were male. The patient s age at the time of presentation varies from 15 years to 60 years with a mean of 31 years (SD years). Out of 87 patients, 73 (83.9%) patients were under the age of 40 years. Figure 1 show the various systems involved in SLE patients. Most common features involved in these patients were immunological (97.7%), mucocutaneous (83.9%), hematological (72.4%) and renal (69.0%). Table 1 shows the clinical profile of all SLE patients. Among the various mucocutaneous manifestation, malar rash was the most common clinical feature presented in 62 (71.3%) patients followed by photosensitivity and oral ulcers in 55 (63.2%) and 37 (42.5%) patients respectively. Renal involvement was present in 60 (69%) patients 34
3 and hemolytic anemia was present in 13 (14.9%) and 7 (8.1%) patients respectively. Regarding immunological profile, 85 patients (97.7%) were positive for ANA. Data about anti-ds DNA antibodies was available for 49 patients, out of which 46 (94%) were found to be positive. Figure 1: arious systems involved in systemic lupus erythematosus patients (n 8 ) Table 1: Clinical and immunological profile of SLE patients Variables No. of cases (%) Age distribution <20 years 19 (21.8) years 54 (62.1) >40 years 14 (16.1) Sex distribution Male 2 (2.3) Female 85 (97.7) Clinical features Mucocutaneous manifestation Malar rash 62 (71.3) Discoid rash 28 (32.2) Alopecia 9 (10.34) Oral ulcer 37 (42.53) Photosensitivity 55 (63.2) Hematological Hemolytic anemia 7 (8.1) Leucopenia 16 (18.4) Lymphopenia 42 (48.3) Thrombocytopenia 13 (14.9) Renal Proteinuria (>0.5 g/d) 57 (65.5) Elevated serum creatinine 21 (25.3) Active urinary cast 3 (3.5) Neurological Psychosis 3 (3.5) Seizures 0 CVA 1 (1.15) Musculoskeletal Arthralgia 46 (52.9) Non-specific symptom (unexplained fever, myalgia) 72 (82.8) Serositis Pleural effusion 6 (6.9) Pericardial effusion 2 (2.3) Antinuclear antibodies 85 (97.7) Anti-Ds antibodies (49/87) 46 (93.9) SLE - Systemic lupus erythematosus, CVA - Cerebrovascular accidents of whom the most common feature was proteinuria in 57 (65.5%) patients followed by deranged creatinine and active urinary sediment in 21 (25.3%) and 3 (3.5%) patients respectively. Hematological features were found in 63 (72.4%) patients. Lymphopenia ( 1,500/cumm) was the most common hematological abnormality present in 42 patients (48.3%) followed by leucopenia ( 4,000/cumm) in 16 patients (18.5%). Thrombocytopenia ( 100,000/ cumm) Arthralgia was noticed in 46 patients (52.9%). Regarding neurological problems, 3 patients (3.5%) were found to have psychosis and 1 (1.2%) patient suffered an ischemic stroke. With respect to pulmonary and cardiac involvement, 6 patients (7%) were found to have pleural effusion and 2 patients (2.3%) had pericardial effusion. 3 patients (3.5%) were suffering from interstitial fibrosis and 2 patients had pulmonary tuberculosis. DISCUSSION In the present study of clinical and immunological profile of hospitalized SLE patients, we found that the disease was more common in female patients especially during the child bearing age group. Our study showed higher frequency of immunological, mucocutaneous, hematological and renal involvement in hospitalized patients. Involvement of neurological, cardiovascular and respiratory system was found to be less common. This study signifies detail clinical examination and focused investigation in patients suspected to have SLE, especially in female patients of child bearing age. Various studies have been conducted from different part of the country regarding clinical and epidemiological of SLE [Table 2]. A study done by Malaviya et al. [9] analyzing 1366 SLE patients from different part of India shows significant high proportion of patients presenting with mucocutaneous manifestations specially arthralgia (85%) malar rash (58.5%) and renal involvement (57%). Similar result has been found in our study showing involvement of mucocutaneous and renal manifestations in 83.9% and 70% patients. Malar rash (71.3%) and fever (82.8%) was the most common clinical feature in the present study. However, studies conducted by Binoy et al. [10] and Kosaraju et al. [11] from the south India have shown less prevalence of mucocutaneous manifestation, which might be because of dark complexion of the study population making it difficult to detect these features. Regional variation has been observed regarding renal involvement in SLE patients ranging from 20% to 73%. Study conducted from the northern [7] and western India [12] has shown high prevalence of renal involvement as compare with south India. [8,10,11] Present study has shown similar finding of high prevalence of renal involvement (69%) in the SLE patients. However, one study conducted from central India has shown less prevalence of renal involvement. [13] Prevalence of neuropsychiatric manifestation among SLE patients varies world-wide with higher prevalence noted 35
4 Table 2: Cumulative percentage frequency of clinical manifestations in patients with SLE from different studies in India Clinical manifestations Malaviya (1988) [7] n=329 (%) Madhavan (1988) [8] n=330 (%) Malaviya (1997) [9] n=1366 (%) Binoy (2003) [10] n=75 (%) Kosaraju (2010) [11] n=48 (%) Saigal (2011) [12] n=60 (%) Present study n=87 (%) Malar rash (n=62) Discoid rash NA NA NA (n=28) Alopecia NA (n=9) Oral ulcer (n=37) Photosensitivity (n=55) Arthralgia (n=46) Fever NA NA NA 82.8 (n=72) Hemolytic anemia (n=7) Leucopenia NA 14.7 NA (n=16) Lymphopenia NA NA NA NA 48.3 (n=42) Thrombocytopenia NA (n=13) Renal (n=60) Neuropsychiatric (n=4) Pulmonary NA NA NA (n=11) Cardiovascular NA 5.3 NA (n=2) ANA (n=85) Ds DNA (n=46/49) NA - Not available, Ds DNA - Double-stranded deoxyribonucleic acid, ANA - Anti-nuclear antibody, SLE - Systemic lupus erythematosus in the Indian patients as compare to other ethnic groups. [14] Study conducted by Malaviya et al. [9] from India has shown that nearly half of the Indian patients of SLE has neuropsychiatric manifestation during the course of illness with more prevalence from the northern India [6] as compare to western or south India. [10-12] Our study showed only 4 patients (4.6%) presenting with neuropsychiatric manifestation. Higher prevalence of neuropsychiatric manifestations in the previous study might be because of inclusion of the broader group of manifestation included in the study population and lack of standard definition given by ACR in Hematological involvement was seen in 72.4% patients in the present study. Among the various hematological criteria defined by ACR, lymphopenia was the most prevalence (48.3%) in our study. This might be because of unregulated cell mediated immunity playing a vital role in the pathogenesis of disease. Other significant hematological abnormality found in the present study was leucopenia (18.4%) and thrombocytopenia (14.9%). Overall prevalence of hematological manifestation has been found to be low in various Indian studies with the highest prevalent found to be in the study conducted by Binoy et al. [10] from western India. Pleuroparenchymal involvement in the form of serositis was present only in 8 patients (9.2%); however, study from North and South India [8,9] have shown higher prevalence of cardiovascular manifestations. ANA is highly sensitive diagnostic test that can be used for screening the patients suspected to have SLE on clinical evaluation. However, because of low specificity it cannot be used for confirmation of disease. Our study shows that nearly 98% of patients were positive for ANA by indirect immunoflorescence method, which was consistence with other studies done from different part of India. However, a study conducted from South India [11] have shown low positivity for ANA (64.28%). The possible explanation for this as given by the author might be because of low titer of ANA to be detected by diagnostic test or not long enough follow-up of patients. In contrast to ANA, anti-ds antibody is highly specific test to confirmation of SLE. Various epidemiological studies from the India have shown positivity of anti-ds DNA antibody ranging from 55% to 76% with the exception of the study conducted from South India, [11] which had high positive result in 89% patients. The present study also has very high percentage of positive anti-ds DNA antibody results (94%). Since we could retrieve the data regarding anti-ds DNA antibody level only in 49 patients (56%), this might be giving high number of a positive result regarding anti-ds DNA antibody. Unlike ANA level, anti-ds DNA antibody level correlates very well with disease severity. [15] Our study has certain strengths. Our study included all the consecutive patients of SLE diagnosed based on American Rheumatology Association criteria to minimize sampling bias. We included all the physician verified clinical features based on their discharge summary for the analysis purpose. However, our study has few limitations. First, since it was a cross-sectional study based on hospitalized patients, it might be possible that more severe SLE patients requiring hospitalization was included in the study and SLE patients presenting on out-patient basis might differ in clinical presentation as compare to in-patients. Hence, this clinical profile of the SLE patients may not be truly representative of clinical profile of SLE patients in the community. Second; since follow-up of these SLE patients was not available; hence, we could not observe the change in clinical profile of these patients as the disease progress. Third, we could obtain anti-ds DNA antibody level only in around half of the 36
5 patients, which might be the reason for very high proportion of patients positive for anti-ds DNA. To conclude, analysis of clinical profile of hospitalized SLE patients shows that the disease is more common in female patients, especially during the child bearing age group. Present study shows high frequency of mucocutaneous, hematological and renal manifestation in these patients. Various geographical variations across the country need to be kept in mind while dealing with these patients. REFERENCES 1. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus 2006;15: Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus 2010;19: Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A. Prevalence of systemic lupus erythematosus in India. Lupus 1993;2: Mondal R, Nandi M, Ganguli S, Ghosh A, Hazra A. Childhood lupus: Experience from Eastern India. Indian J Pediatr 2010;77: Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999;11: Desai SC, Bhandarkar SD. A case report of acute disseminated lupus erythematosus. Indian J Dermatol Venereol 1955;21: Malaviya AN, Singh RR, Kumar A, De A, Kumar A, Aradhye S. Systemic lupus erythematosus in northern India: A review of 329 cases. J Assoc Physicians India 1988;36:476-80, Madhavan R. Systemic lupus erythematosus. The Madras experience. J Assoc Physicians India 1988;36: Malaviya AN, Chandrasekaran AN, Kumar A, Shamar PN. Systemic lupus erythematosus in India. Lupus 1997;6: Binoy JP, Muhammed F, Kumar N, Razia MV. Clinical profile of systemic lupus erythematosus in North Kerala. J Indian Rheumatol Assoc 2003;11: Kosaraju K, Shenoy S, Suchithra U. A cross-sectional hospital-based study of autoantibody profile and clinical manifestations of systemic lupus erythematosus in south Indian patients. Indian J Med Microbiol 2010;28: Saigal R, Kansal A, Mittal M, Singh Y, Maharia HR, Juneja M. Clinical profile of systemic lupus erythematosus patients at a tertiary care centre in Western India. J Indian Acad Clin Med 2011;13: Shantaram V, Das UN, Srinivasan VR. Clinical profile of systemic lupus erythematosus-nizam Institute of Medical Sciences (Hyderabad) experience. J Indian Rheumatol Assoc 1995;3 Suppl: Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010;9:A Kumar A. Indian guideline on the management of SLE. J Indian Rheumatol Assoc 2002;10: How to cite this article: Agrawal SR, Tiewsoh I, Rajput A, Jain A. A of systemic lupus erythematosus patients from central rural India. Indian J Allergy Asthma Immunol 2013;27:33-7. Source of Support: Nil, None declared. Staying in touch with the journal 1) Table of Contents (TOC) alert Receive an alert containing the TOC when a new complete issue of the journal is made available online. To register for TOC alerts go to 2) RSS feeds Really Simple Syndication (RSS) helps you to get alerts on new publication right on your desktop without going to the journal s website. You need a software (e.g. RSSReader, Feed Demon, FeedReader, My Yahoo!, NewsGator and NewzCrawler) to get advantage of this tool. RSS feeds can also be read through FireFox or Microsoft Outlook Once any of these small (and mostly free) software is installed, add as one of the feeds. 37
Original Article. Abstract
Original Article Diagnostic accuracy of antinuclear antibodies and anti-double stranded DNA antibodies in patients of systemic lupus erythematosus presenting with dermatological features Attiya Tareen*,
More informationCutaneous manifestations and systemic correlation in patients with lupus erythematosus and its subsets: a study of 40 cases
International Journal of Research in Dermatology Mahajan R et al. Int J Res Dermatol. 2018 Nov;4(4):479-483 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20183407
More informationDr. Venkateswari. R. Dr. Janani Sankar s unit Kanchi Kamakoti CHILDS Trust Hospital
Dr. Venkateswari. R. Dr. Janani Sankar s unit Kanchi Kamakoti CHILDS Trust Hospital Acknowledgements: KKCTH Dr. Ramkumar Consultant Dermatologist Dr. Ramprakash Consultant Ophthalmologist Dr. Prasad Manne
More informationHigh Impact Rheumatology
High Impact Rheumatology Systemic Lupus Erythematosus Bernard Rubin, DO MPH Case 1: History A 45-year-old woman presents with severe dyspnea and cough. She was in excellent health until 4 weeks ago when
More informationSystemic Lupus Erythematosus among Jordanians: A Single Rheumatology Unit Experience
Systemic Lupus Erythematosus among Jordanians: A Single Rheumatology Unit Experience Ala M. AlHeresh MD* ABSTRACT Objectives: To study the characteristics of Systemic Lupus Erythematosus in Jordan and
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationDefinition Chronic autoimmune disease The body s immune system starts attacking itself Can affect most organs and tissues in the body Brain, lungs, he
LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. Rowan Diagnostic Clinic Salisbury, N.C. May 11, 2013 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationLUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS LUPUS 101 SLE SUBSETS AUTOIMMUNE DISEASE 11/4/2013 HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS
LUPUS 101 LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS SLE SUBSETS SUBACUTE CUTANEOUS LUPUS DRUG INDUCED LUPUS NEONATAL LUPUS LATE ONSET LUPUS ANTI-PHOSPHOLIPID
More informationUPDATES ON PEDIATRIC SLE
UPDATES ON PEDIATRIC SLE BY ANGELA MIGOWA, PEDIATRIC RHEUMATOLOGIST/SENIOR INSTRUCTOR AKUHN MBCHB-UON, MMED-AKUHN,PEDIATRIC RHEUMATOLOGY- MCGILL UNIVERSITY HEALTH CENTRE ROSA PARKS OBJECTIVES RECOGNIZE
More informationLiving with Lupus: An Insider s Perspective
Living with Lupus: An Insider s Perspective Pamela Thorpe, MD, FACP Lupus Foundation of America, Inc. Philadelphia Tri-State Chapter Volunteer May 2014 My Own Story Is it Lupus Yet? The What What is this?
More informationUNDERSTANDING SYSTEMIC LUPUS ERYTHEMATOSUS
UNDERSTANDING SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. October 20, 2012 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement Diagnosis Treatment Pregnancy
More informationGender Differences in the Clinical and Serological Features of Systemic Lupus Erythematosus in Malaysian Patients
o ORIGINAL ARTICLE Gender Differences in the Clinical and Serological Features of Systemic Lupus Erythematosus in Malaysian Patients M R Azizah, MBBCh*, S S Ainol, MMed**, N C T Kong, MRCP***, Y Normaznah,
More information9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 1 Other Types of Lupus Discoid Lupus Erythematosus Lupus Pernio --- Sarcoidosis Lupus Vulgaris --- Tuberculosis of the face Manifestations of SLE Fever Rashes Arthritis
More information.,Dr Ali Alkazzaz Babylon collage of medicine 2016
.,Dr Ali Alkazzaz Babylon collage of medicine 2016 Lupus history Lupus is the Latin word for wolf 1 st used medically in the 10 th century Described clinically in the 19 th century Butterfly rash in 1845
More informationMANAGING THE PATIENT WITH POSITIVE ANA
MANAGING THE PATIENT WITH POSITIVE ANA Rafael F. Rivas-Chacon, M.D. Disclosures Grant/Research support for: Pfizer Study JIA A3921104 Tofacitinib not related to this presentation 1 Positive Antinuclear
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationLUPUS (SLE) MEDICAL SOURCE STATEMENT
LUPUS (SLE) MEDICAL SOURCE STATEMENT From: Re: (Name of Patient) (Social Security No.) Please answer the following questions concerning your patient s impairments. Attach relevant treatment notes, radiologist
More informationInsights into the DX of Pediatric SLE
Insights into the DX of Pediatric SLE Dr. John H. Yost Pediatric Rheumatology Children s Hospital at Dartmouth Assistant Professor of Medicine Geisel School of Medicine at Dartmouth john.h.yost@hitchcock.org
More informationSystemic Lupus Erythematosus in Libyan Children: Diagnosis and Management
Research Article imedpub Journals www.imedpub.com ARCHIVES OF MEDICINE DOI: 10.21767/1989-5216.1000276 Abstract Systemic Lupus Erythematosus in Libyan Children: Diagnosis and Management Background: Childhood
More informationSystemic Lupus Erythematosus
Systemic Lupus Erythematosus Marc C. Hochberg, MD, MPH Professor of Medicine and Head, Division of Rheumatology University of Maryland School of Medicine CASE: HISTORY A 26-year-old woman is seen for migratory
More informationSystemic examination
PROLONGED FEVER IN AN ADOLESCENT BOY Dr.Praveena Lionel, DNB PG, Dr.Kannan (HOD) Railway Hospital, Perambur History 11 yrs old adolescent boy was admitted with c/o Fever -1 wk Myalgia -1 wk Arthralgia
More informationPeter H. Schur Elena M. Massarotti. Editors. Lupus Erythematosus. Clinical Evaluation and Treatment
Lupus Erythematosus Peter H. Schur Elena M. Massarotti Editors Lupus Erythematosus Clinical Evaluation and Treatment Editors Peter H. Schur Division of Rheumatology, Immunology, Allergy Brigham and Women
More informationCorrelation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies
Original Article Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies Col K Narayanan *, Col V Marwaha +, Col K Shanmuganandan #, Gp Capt S Shankar
More informationCentral Nervous System (CNS) and Lupus: Learn from the Experts. Betty Diamond, M.D. Feinstein Institute for Medical Research
Central Nervous System (CNS) and Lupus: Learn from the Experts Betty Diamond, M.D. Feinstein Institute for Medical Research Stages in SLE Pathogenesis Crow MK, Arth Res & Tx. 2009 ACR Criteria for the
More informationSignificance of Anti-C1q Antibodies in Patients with Systemic Lupus Erythematosus as A Marker of Disease Activity and Lupus Nephritis
THE EGYPTIAN JOURNAL OF IMMUNOLOGY Vol. 23 (1), 2016 Page: 00-00 Significance of Anti-C1q Antibodies in Patients with Systemic Lupus Erythematosus as A Marker of Disease Activity and Lupus Nephritis 1
More informationLate onset systemic lupus erythematosus in southern Chinese. Citation Annals Of The Rheumatic Diseases, 1998, v. 57 n. 7, p.
Title Late onset systemic lupus erythematosus in southern Chinese Author(s) Ho, CTK; Mok, CC; Lau, CS; Wong, RWS Citation Annals Of The Rheumatic Diseases, 1998, v. 57 n. 7, p. 437-440 Issued Date 1998
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationPSYCHIATRIC MANIFESTATIONS IN PEDIATRIC SLE PATIENTS AT SIRIRAJ HOSPITAL BANGKOK, THAILAND
PSYCHIATRIC MANIFESTATIONS IN PEDIATRIC SLE PATIENTS AT SIRIRAJ HOSPITAL BANGKOK, THAILAND Sasitorn Chantaratin, Prae Wongtangman, Sudrat Sirisakpanit and Vitharon Boon-yasidhi Division of Child and Adolescent
More informationCommunity response to noise
Community response to noise Takashi Yano, Truls Gjestland 1, Soogab Lee 2 Department of Architecture, Graduate School of Science and Technology, Kumamoto University, Kurokami 2-39-1, Chuo-Ku, Kumamoto
More informationNATIONAL LABORATORY HANDBOOK. Laboratory Testing for Antinuclear antibodies
NATIONAL LABORATORY HANDBOOK Laboratory Testing for Antinuclear antibodies Document reference number CSPD013/2018 Document developed by National Clinical Programme for Pathology Revision number Version
More informationPattern of Systemic Lupus Erythematosus in Tabuk, Saudi Arabia
Original article: Pattern of Systemic Lupus Erythematosus in Tabuk, Saudi Arabia Abdullah ALYOUSSUF 1, Bashar ALASSAR 2, Osama MOHAMMED*, 1, Hyder MIRGHANI 1, Palanisamy Amirthalingam 3 1Department of
More informationTest Name Results Units Bio. Ref. Interval
135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final RHEUMATOID AUTOIMMUNE COMREHENSIVE ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), SERUM ----- 20-60
More informationThe Diagnosis of Lupus
The Diagnosis of Lupus LUPUSUK 2017 This information booklet has been produced by LUPUS UK 2017 LUPUS UK LUPUS UK is the registered national charity for people with systemic lupus erythematosus (SLE) and
More informationResearch Article Hematological Manifestations of SLE at Initial Presentation: Is It Underestimated?
International Scholarly Research Network ISRN Hematology Volume 2012, Article ID 961872, 5 pages doi:10.5402/2012/961872 Research Article Hematological Manifestations of SLE at Initial Presentation: Is
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Belimumab Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 11/15/2017 Next
More informationInternational Journal of Pharma and Bio Sciences A STUDY OF CLINCAL PROFILE IN DENGUE CASES ABSTRACT
Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 A STUDY OF CLINCAL PROFILE IN DENGUE CASES DHANDAPANI E.* 1 AND SUDHA M 2 1 Formerly Professor of Medicine,
More informationLupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?
Lupus Systemic lupus erythematosus, referred to as SLE or lupus, is sometimes called the "great imitator." Why? Because of its wide range of symptoms, people often confuse lupus with other health problems.
More informationSummary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z
Topic Page: Systemic Lupus Erythematosus Summary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z What Is It? Lupus is thought to develop when the immune system
More informationSection: Medicine Effective Date: January 15, 2016 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject:
Last Review Status/Date: December 2015 Page: 1 of 11 Summary Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease that can be difficult to diagnose because patients often present
More informationPolicy. Background
Last Review Status/Date: December 2016 Page: 1 of 11 Summary Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease that can be difficult to diagnose because patients often present
More informationResidual Functional Capacity Questionnaire SYSTEMIC LUPUS ERYTHEMATOSUS
Residual Functional Capacity Questionnaire SYSTEMIC LUPUS ERYTHEMATOSUS Patient: DOB: Physician completing this form: Please complete the following questions regarding this patient's impairments and attach
More informationConflict of Interest. Systemic Lupus Erythematosus and the Antiphospholipid Syndrome Bonnie L. Bermas, MD Brigham and Women s Hospital.
Systemic Lupus Erythematosus and the Antiphospholipid Syndrome Bonnie L. Bermas, MD Brigham and Women s Hospital Conflict of Interest Disclosures: None Overview Diagnostic Classification Criteria of SLE
More informationRheumatology 101 A Pediatrician s Guide
Rheumatology 101 A Pediatrician s Guide Pediatric Staff and Alumni Day 2016 Dawn M. Wahezi, Yonit Sterba, Tamar Rubinstein Disclosures None Pick a Group Group 1 A child with a limp Group 2 ANA To test
More informationPolicy. Section: Medicine Effective Date: January 15, 2015 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject:
Last Review Status/Date: December 2014 Page: 1 of 10 Summary Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease that can be difficult to diagnose because patients often present
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed: &
Systemic Lupus Erythematosus Pre-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: & HSCT type: o autologous o allogeneic, o
More informationClinical Features and Outcome of Systemic Lupus Erythematosus
SHORT COMMUNICATION Clinical Features and Outcome of Systemic Lupus Erythematosus INDIRA AGARWAL, T SATHISH KUMAR, KALA RANJINI, CHELLAM KIRUBAKARAN AND *DEBASHISH DANDA From the Departments of Child Health
More informationClinical and immunological characteristics of Polish patients with systemic lupus erythematosus
Original papers Clinical and immunological characteristics of Polish patients with systemic lupus erythematosus Martyna Tomczyk-Socha 1, B E, Hanna Sikorska-Szaflik 2, B E, Marek Frankowski 3, B D, Karolina
More information* Autoantibody positive (i.e. antinuclear antibody or ANA titre 1:80 or anti-double stranded (ds) DNA antibody 30 IU/mL)
Benlysta (belimumab) Policy Number: 5.02.509 Last Review: 05/2018 Origination: 06/2011 Next Review: 05/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Benlysta
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: belimumab_benlysta 6/2011 2/2018 2/2019 3/2018 Description of Procedure or Service Belimumab (Benlysta) is
More informationSystemic lupus erythematosus (SLE) ... PRESENTATIONS... Epidemiology of Systemic Lupus Erythematosus. Based on a presentation by Susan Manzi, MD, MPH
... PRESENTATIONS... Epidemiology of Systemic Lupus Erythematosus Based on a presentation by Susan Manzi, MD, MPH Presentation Summary Tracking the epidemiology of systemic lupus erythematosus is problematic
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091593 Age 25 Years Gender Male 30/8/2017 91600AM 30/8/2017 93946AM 31/8/2017 84826AM Ref By Final COLLAGEN DISEASES ANTIBODY ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF),
More informationStudy of Interleukin-12 Cytokine and Anti-C1q Antibodies in Lupus Nephritis Patients
International Journal of Internal Medicine 214, 3(1): 13-26 DOI: 1.5923/j.ijim.21431.3 Study of Interleukin-12 Cytokine and Anti-C1q Antibodies in Lupus Nephritis Patients Mohamed N. AL Alfy 1,*, Mohamed
More informationAutoimmune Disease. Autoimmunity. Epidemiology. ACR Criteria for Diagnosis. Signs and Symptoms. Autoreactivity: Reactivity to self antigens:
Autoimmunity Reactivity to self antigens: Autoreactivity: Autoimmune Disease T cells B cells Leading to tissue damage or dysfunction Occurring in the absence of ongoing infection Epidemiology SLE Pathogenesis
More informationAutoimmunity. Autoimmune Disease
Autoimmunity Reactivity to self antigens: T cells B cells Autoimmune Disease Autoreactivity: Leading to tissue damage or dysfunction Occurring in the absence of ongoing infection 1 SLE Pathogenesis Immune
More informationSevere Dengue Infection in ICU. Shirish Prayag MD, FCCM Pune, India
Severe Dengue Infection in ICU Shirish Prayag MD, FCCM Pune, India Greetings from India Declaration Honararia from MSD, Astra Zenecea, Fresenius Kabi, Pfizer, Intas, Glenmark for conducting lectures. No
More informationSerum Biomarker Panel Testing for Systemic Lupus Erythematosus
Serum Biomarker Panel Testing for Systemic Lupus Erythematosus Policy Number: 2.04.123 Last Review: 8/2017 Origination: 8/2015 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationDemystifying. Systemic Lupus Erythematosus: Signs and Symptoms for Early Recognition. Teaching Fellows in Lupus Project
Demystifying Systemic Lupus Erythematosus: Signs and Symptoms for Early Recognition Teaching Fellows in Lupus Project Introduction: Why are we here? Lupus can take 4-6 years and 3 providers before diagnosis*
More informationClinical Study A Study on Clinical and Pathologic Features in Lupus Nephritis with Mainly IgA Deposits and a Literature Review
Clinical and Developmental Immunology Volume 2013, Article ID 289316, 5 pages http://dx.doi.org/10.1155/2013/289316 Clinical Study A Study on Clinical and Pathologic Features in Lupus Nephritis with Mainly
More informationSLE and the Antiphospholipid Syndrome
SLE and the Antiphospholipid Syndrome Susan Y. Ritter MD, PhD Associate Physician Division of Rheumatology, Immunology and Allergy Department of Medicine Brigham and Women s Hospital Instructor in Medicine
More informationPS + MPs PS - MPs 37% 36% 64% 64%
Supplementary Figure 1. Amount and distribution of phosphatidylserine negative (PS - ) and phosphatidylserine positive (PS + ) MPs in 280 SLE patients and 280 controls. Circles are proportional to the
More informationPulmonary Function Tests In Patients with Systemic Lupus Erythematosus (SLE)
Pulmonary Function Tests In Patients with Systemic Lupus Erythematosus (SLE) Samiha Samuel, Mona Mohsen, Rasha M. Gamal El-Din, and Hossam Hosny 2 From the Departments of Pediatrics, Children s Hospital,
More informationClinical and Laboratory Features of Systemic Lupus Erythematosus (SLE) in Pakistani Patients
Clinical and Laboratory Features of Systemic Lupus Erythematosus (SLE) in Pakistani Patients T. A. Ahmed ( Department of Immunology, Armed Forces Institute of Pathology (AFIP), Rawalpindi ) N. llcram,t.
More informationLi-Lan Chiang 1, Yu-Tsan Lin 1, Hung-Yi Chan 1 and Bor-Luen Chiang 1,2* Abstract
Chiang et al. Pediatric Rheumatology 2012, 10:12 RESEARCH Open Access Differential manifestations of prepubescent, pubescent and postpubescent pediatric patients with systemic lupus erythematosus: A retrospective
More informationSIADH as Presenting Feature in a Male with Coexisting Sarcoidosis and Systemic Lupus
SIADH as Presenting Feature in a Male with Coexisting Sarcoidosis and Systemic Lupus Santhiya Govindaraj 1, Stalin Viswanathan 2, Bhavith Remalayam 1, Balamurugesan Kandan 2, Shanthi Kumar 3 1 Department
More informationSystemic lupus erythematosus in a male patient
IOP Conference Series: Earth and Environmental Science PAPER OPEN ACCESS Systemic lupus erythematosus in a male patient To cite this article: H Sibarani and Z Zubir 2018 IOP Conf. Ser.: Earth Environ.
More informationEvidence Based Treatment of SLE with Treatment Algorithm. Dr. Md. Mujibur Rahman Professor of Medicine Shaheed Suhrawardy Medical College
Evidence Based Treatment of SLE with Treatment Algorithm Dr. Md. Mujibur Rahman Professor of Medicine Shaheed Suhrawardy Medical College Natural Histoty Inflammatory multisystem disease Onset usually between
More informationAutoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic
SLIDE 3: Introduction to autoimmune diseases Chronic Autoimmune diseases Sometimes relapsing : and remitting. which means that they present as attacks Progressive damage Epitope spreading more and more
More informationReporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation
Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Marcelo C. Pasquini, MD, MSc HVD05_1.ppt Outline Review of autoimmune diseases (AID). Role of transplantation for AID Data collection:
More informationFever in Lupus. 21 st April 2014
Fever in Lupus 21 st April 2014 Fever in lupus Cause of fever N= 487 % SLE fever 206 42 Infection in SLE 265 54.5 Active SLE and infection 8 1.6 Tumor fever 4 0.8 Miscellaneous 4 0.8 Crucial Question Infection
More informationMarilina Tampoia, MD; Vincenzo Brescia, MD; Antonietta Fontana, MD; Antonietta Zucano, PhD; Luigi Francesco Morrone, MD; Nicola Pansini, MD
Application of a Combined Protocol for Rational Request and Utilization of Antibody Assays Improves Clinical Diagnostic Efficacy in Autoimmune Rheumatic Disease Marilina Tampoia, MD; Vincenzo Brescia,
More informationIntroduction. 1. Introduction
1. Introduction Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiologic processes associated with abnormal kidney function, and a progressive decline in glomerular filtration
More informationAsk the Expert: Photosensitivity in Cutaneous Lupus
Ask the Expert: Photosensitivity in Cutaneous Lupus Victoria P. Werth, MD Department of Dermatology & Medicine University of Pennsylvania ; Philadelphia VA Hospital Overview Definition Impact of photosensitivity
More informationAssociations between SLE and spontaneous IFN-g release. Jenna Thomason, MD, MPH Grant Hughes, MD April 29, 2017
Associations between SLE and spontaneous IFN-g release Jenna Thomason, MD, MPH Grant Hughes, MD April 29, 2017 None Disclosures Outline Background Methods Preliminary results Conclusions March, 1980 IFN-g
More informationPleuropulmonary Manifestations in Juvenile Systemic Lupus Erythematosus; A Review and Descriptive Study in 64 Cases
Original Article Iran J Pediatr Mar 2008; Vol 18 ( No 1), Pp:47-52 Pleuropulmonary Manifestations in Juvenile Systemic Lupus Erythematosus; A Review and Descriptive Study in 64 Cases Mohammad Hassan Moradinejad*
More informationMarket Access CTR Summary
Market Access CTR Summary Study No.: BEL114246 Title: Efficacy of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: A Pooled Analysis of the HGS1006-C1056 (BLISS-52)
More informationSystemic lupus erythematosus (SLE) is a. Paediatrica Indonesiana
VOLUME 43 November - December 2003 NUMBER 11-12 Original Article Clinical and laboratory manifestations of childhood and adult-onset systemic lupus erythematosus in Cipto Mangunkusumo Hospital Syarif Faisal,
More informationMP Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases
Medical Policy MP 2.04.123 Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases BCBSA Ref. Policy: 2.04.123 Last Review: 06/27/2018 Effective Date: 06/27/2018
More information9/13/2015. Nothing to disclose
Jared Bozeman Kathleen Luskin MD Bipin Thapa MD Medical College of Wisconsin Milwaukee, Wisconsin Nothing to disclose 24 Year old previously healthy woman presenting from OSH Fatigue Weakness Neck swelling
More informationLupus Erythematosus - Can Anti-SS-A Antibody Predict the Next Event?
Original Article Thrombocytopenia Subsequently Develops Systemic Lupus Erythematosus - Can Anti-SS-A Antibody Predict the Next Event? Masanori ADACHI*, Seiji MlTA, Mitsuo OBANA, Yasuo MATSUOKA,Keiichi
More information2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.
Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis
More informationSerum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases
Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases Policy Number: 2.04.123 Last Review: 8/2018 Origination: 8/2015 Next Review: 8/2019 Policy Blue Cross
More informationBudsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital
Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases Outline What is ANA? How to detect ANA? Clinical
More informationRheumatology Primer: What Labs and When
Rheumatology Primer: What Labs and When Irina Konon, MD Department of Internal Medicine Division of Rheumatology Medical College of Wisconsin Disclosures None 1 Objective Discuss principles of laboratory
More informationMyositis and Your Lungs
Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes
More informationInternal Medicine Certification Examination Blueprint
Internal Medicine Certification Examination Blueprint What Does the Examination Cover? The exam is designed to evaluate the extent of the candidate s knowledge and clinical judgment in the areas in which
More informationHow the Innate Immune System Profiles Pathogens
How the Innate Immune System Profiles Pathogens Receptors on macrophages, neutrophils, dendritic cells for bacteria and viruses Broad specificity - Two main groups of bacteria: gram positive, gram-negative
More informationCHAPTER 3. Secondary Glomerulonephritis
2nd Report of the Malaysian Registry of Renal Biopsy 2008 SECONDARY GLOMERULONEPHRITIS CHAPTER 3 Secondary Glomerulonephritis Rosnawati Yahya Liew Yew Foong 41 SECONDARY GLOMERULONEPHRITIS 2nd Report
More informationLupus The Clinical Perspective
Lupus The Clinical Perspective Anca D. Askanase, M.D., M.P.H. Associate Professor of Medicine Director Lupus Center Columbia University Medical Center New York-Presbyterian Hospital Systemic Lupus Erythematosus
More informationList of Chapters. 5. Care of the sick child Evidence-based pediatrics (page 77 to 80)
Illustrated Textbook of Paediatrics, 4th Edition Tom Lissauer, and Graham Clayden, 2012 List of Chapters 1. The child in society 2. History and examination 3. Normal child development, hearing and vision
More informationAAF Case Discussion Guide Key Learning Objectives
AAF Case Discussion Guide Key Learning Objectives List the differential diagnosis for a systemic disease presentation with multisystem involvement. Identify the key questions from the history to look for
More informationTable of Contents. Course CME Credits. General Principles Topic CME Credit(s)
Table of Contents Course Course CME Credits Med-Challenger SPEX Comprehensive Review 266.0 CME Credits General Principles 21.0 CME Credit(s) Abdominal Pain 1.0 Acute Pelvic Pain in Women 1.0 Acute Vaginal
More informationJuvenile-Onset versus Adult-Onset Systemic Lupus Erythematosus: Different Clinical and Serological Patterns
Original Article Juvenile-Onset versus Adult-Onset Systemic Lupus Erythematosus: Different Clinical and Serological Patterns Dalia Fayez Mohamed 1, Amina Badr El- Din Abdel Aziza 1, Sameh Abdel-Moteleb
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Comparative Study of Primary & Secondary Dengue in a Tertiary Care Centre Sheeba P.M 1, Arun
More informationEarly diagnosis of systemic lupus erythematosus in primary care by family doctors
ISSN 2229-5518 2,302 Early diagnosis of systemic lupus erythematosus in primary care by family doctors Saad Ali Alalyani, Abdullah Saad Alalyani, Sultan Salem Algethami, Hamad Sulayyih Alosaimi, Abdullah
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients
More informationRENAL FAILURE IN CHILDREN Dr. Mai Mohamed Elhassan Assistant Professor Jazan University
RENAL FAILURE IN CHILDREN Dr. Mai Mohamed Elhassan Assistant Professor Jazan University OBJECTIVES By the end of this lecture each student should be able to: Define acute & chronic kidney disease(ckd)
More informationORIGINAL ARTICLE. A STUDY ON CLINICAL, LABORATORY PROFILE AND OUTCOME OF DENGUE FEVER Vanamali D.R 1, L. Venugopal 2, P. Yeshwanth 3, Dilip Rampure 4
A STUDY ON CLINICAL, LABORATORY PROFILE AND OUTCOME OF DENGUE FEVER Vanamali D.R 1, L. Venugopal 2, P. Yeshwanth 3, Dilip Rampure 4 HOW TO CITE THIS ARTICLE: Vanamali D.R, L. Venugopal, P. Yeshwanth, DilipRampure.
More information